Hepatitis C Combination Therapy - FDA Grants Fast Track Designation to Vertex's Investigational Oral

FDA Grants Fast Track Designation to Vertex's Investigational Oral
PR Newswire - CAMBRIDGE, Mass., Dec. 8 /PRNewswire-FirstCall/ -- Vertex PharmaceuticalsIncorporated (Nasdaq: VRTX) today announced that the U.S. Track designation to VX-950for the following reasons: *

and Ribavirin in Nonresponders with
HIV and Hepatitis.com - Valeant will pay InterMune $113.5 million in cash upon closing, and subsequent milestone payments of up to approximately $22.5 million. Valeant also will acquire an estimated $6.5 million in inventory from InterMune.

GlobeImmune Relocates Corporate Headquarters
Pharma Live - LOUISVILLE, Colo., December 15, 2005 /PRNewswire/ -- GlobeImmune, Inc. today announced the relocation of its corporate headquarters to Louisville, Colorado. 1b trial for its second product, GI-5005, a Tarmogen for the treatment of

Treatment of Genotype 1
HIV and Hepatitis.com - RBV dose reductions also are associated with decreased SVR.